Coder-rony commited on
Commit
d51a77e
·
verified ·
1 Parent(s): d24724c

validated shard 357

Browse files
Files changed (1) hide show
  1. validated/shard_00357.jsonl +5 -0
validated/shard_00357.jsonl ADDED
@@ -0,0 +1,5 @@
 
 
 
 
 
 
1
+ {"session_id": "atlas-109e943760", "tier": "text", "task_instruction": "Determine the standard treatment protocol for acute promyelocytic leukemia (APL) and identify potential complications.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "The passage mentions that M3 subtype of AML, also known as APL, is almost universally treated with ATRA.", "image_path": null, "audio_path": null}, "reasoning": "So, ATRA is a key component of the standard treatment.", "action": {"type": "text_response", "value": "Identify ATRA as part of the standard treatment."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "It also states that induction chemotherapy, usually an anthracycline, is used alongside ATRA.", "image_path": null, "audio_path": null}, "reasoning": "This means that the standard treatment combines ATRA with an anthracycline.", "action": {"type": "text_response", "value": "Recognize that the treatment protocol includes both ATRA and an anthracycline."}, "refers_back_to": null}, {"step_index": 2, "observation": {"text": "The passage highlights the need to prevent disseminated intravascular coagulation (DIC) as a complication.", "image_path": null, "audio_path": null}, "reasoning": "DIC is a potential complication that arises when promyelocytes release granule contents into the circulation.", "action": {"type": "text_response", "value": "Note that DIC is a significant complication that must be managed during treatment."}, "refers_back_to": null}, {"step_index": 3, "observation": {"text": "APL is noted to be eminently curable with well-documented treatment protocols.", "image_path": null, "audio_path": null}, "reasoning": "This indicates that with proper treatment, the prognosis for APL is very positive.", "action": {"type": "text_response", "value": "Understand that the curability rate is high with established treatment protocols."}, "refers_back_to": null}], "task_complexity": "low", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-17", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "The M3 subtype of AML , also known as acute promyelocytic leukemia ( APL ) , is almost universally treated with the drug all @-@ trans @-@ retinoic acid ( ATRA ) in addition to induction chemotherapy , usually an anthracycline . Care must be taken to prevent disseminated intravascular coagulation ( DIC ) , complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation . APL is eminently curable , with well @-@ documented treatment protocols .", "_validation_note": "<reasoning> for each step: (1) the reasoning correctly identifies ATRA as a key component of the standard treatment, (2) the reasoning accurately connects ATRA with an anthracycline in the treatment protocol, (3) the reasoning correctly identifies DIC as a significant complication, and (4) the reaso"}
2
+ {"session_id": "atlas-a49962b215", "tier": "text", "task_instruction": "Determine the likelihood of achieving complete remission for a newly diagnosed adult with acute lymphoblastic leukemia (ALL) considering the provided passage.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "The passage states that complete remission is achieved by 50%–75% of newly diagnosed adults.", "image_path": null, "audio_path": null}, "reasoning": "Given that the individual is a newly diagnosed adult with ALL, which is a type of leukemia, the likelihood of achieving complete remission is within this range.", "action": {"type": "text_response", "value": "Assess that the likelihood is between 50% and 75%."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "The passage mentions that this rate may vary based on prognostic factors.", "image_path": null, "audio_path": null}, "reasoning": "Prognostic factors such as the type of leukemia, patient's age, and overall health can influence the likelihood of achieving remission.", "action": {"type": "text_response", "value": "Consider that individual prognostic factors could increase or decrease the likelihood."}, "refers_back_to": null}, {"step_index": 2, "observation": {"text": "The passage emphasizes that all remissions will fail without additional consolidation therapy.", "image_path": null, "audio_path": null}, "reasoning": "This means that achieving remission is just the first step, and further treatment is necessary to maintain it.", "action": {"type": "text_response", "value": "Recognize the importance of consolidation therapy in the treatment plan."}, "refers_back_to": null}], "task_complexity": "high", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-17", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "The goal of the induction phase is to reach a complete remission . Complete remission does not mean the disease has been cured ; rather , it signifies no disease can be detected with available diagnostic methods . Complete remission is obtained in about 50 % – 75 % of newly diagnosed adults , although this may vary based on the prognostic factors described above . The length of remission depends on the prognostic features of the original leukemia . In general , all remissions will fail without additional consolidation therapy .", "_validation_note": "The reasoning provided is correct, the response is correct, and the explanation is coherent."}
3
+ {"session_id": "atlas-7f206496f3", "tier": "text", "task_instruction": "Determine whether additional therapy is required after achieving complete remission in AML.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "Complete remission means all detectable leukemia cells are gone.", "image_path": null, "audio_path": null}, "reasoning": "However, current diagnostic methods can't detect very low levels of leukemic cells.", "action": {"type": "text_response", "value": "Therefore, there might still be residual leukemia cells present."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "If no further therapy is given after remission, almost all AML patients relapse.", "image_path": null, "audio_path": null}, "reasoning": "This suggests that residual leukemia cells can still cause disease progression.", "action": {"type": "text_response", "value": "Hence, additional therapy is necessary to eliminate these undetected cells."}, "refers_back_to": null}], "task_complexity": "low", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-17", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "Even after complete remission is achieved , leukemic cells likely remain in numbers too small to be detected with current diagnostic techniques . If no further postremission or consolidation therapy is given , almost all people with AML will eventually relapse . Therefore , more therapy is necessary to eliminate nondetectable disease and prevent relapse — that is , to achieve a cure .", "_validation_note": "Step 1: <reason> -- The reasoning is logical, suggesting additional therapy is necessary based on the relapse observation, which is sensible and coherent."}
4
+ {"session_id": "atlas-6aa77fcb80", "tier": "text", "task_instruction": "Determine the best postremission therapy for an intermediate-risk AML patient considering their age, health, and donor availability.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "The patient has intermediate-risk AML with normal cytogenetics.", "image_path": null, "audio_path": null}, "reasoning": "Based on the passage, intermediate-risk AML patients don't have clear best therapy options. The decision depends on age, health, donor availability, and personal values.", "action": {"type": "text_response", "value": "Assess the patient's age, overall health, and whether a suitable donor is available."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "The patient is 65 years old with comorbidities affecting their overall health.", "image_path": null, "audio_path": null}, "reasoning": "Given the patient's age and health, allogeneic stem cell transplantation may be too risky. Consolidation chemotherapy might be a safer option.", "action": {"type": "text_response", "value": "Recommend consolidation chemotherapy as it is less intensive than transplantation."}, "refers_back_to": null}, {"step_index": 2, "observation": {"text": "No suitable donor is available for the patient.", "image_path": null, "audio_path": null}, "reasoning": "Without a donor, allogeneic stem cell transplantation is not an option. Therefore, chemotherapy remains the primary choice.", "action": {"type": "text_response", "value": "Proceed with consolidation chemotherapy."}, "refers_back_to": null}], "task_complexity": "high", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-17", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "The specific type of postremission therapy is individualized based on a person 's prognostic factors ( see above ) and general health . For good @-@ prognosis leukemias ( i.e. inv ( 16 ) , t ( 8 ; 21 ) , and t ( 15 ; 17 ) ) , people will typically undergo an additional three to five courses of intensive chemotherapy , known as consolidation chemotherapy . For people at high risk of relapse ( e.g. those with high @-@ risk cytogenetics , underlying MDS , or therapy @-@ related AML ) , allogeneic stem cell transplantation is usually recommended if the person is able to tolerate a transplant and has a suitable donor . The best postremission therapy for intermediate @-@ risk AML ( normal cytogenetics or cytogenetic changes not falling into good @-@ risk or high @-@ risk groups ) is less clear and depends on the specific situation , including the age and overall health of the person , the person 's values , and whether a suitable stem cell donor is available .", "_validation_note": "** The reasoning correctly concludes that without a donor, consolidation chemotherapy is the appropriate choice."}
5
+ {"session_id": "atlas-df91e551fb", "tier": "text", "task_instruction": "Analyze the effect of Ceplene and Proleukin on relapse risk and remission likelihood in ineligible patients.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "The immunotherapy combination reduces absolute relapse risk by 14%.", "image_path": null, "audio_path": null}, "reasoning": "This means the treatment is effective in lowering relapse chances.", "action": {"type": "text_response", "value": "Note the 14% reduction in relapse risk."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "The exact starting relapse risk isn't provided.", "image_path": null, "audio_path": null}, "reasoning": "Without the initial risk, we can't compute the new exact figure.", "action": {"type": "text_response", "value": "Acknowledge the data limitation."}, "refers_back_to": null}, {"step_index": 2, "observation": {"text": "Remission likelihood increases by 50%.", "image_path": null, "audio_path": null}, "reasoning": "This indicates a significant improvement in maintaining remission.", "action": {"type": "text_response", "value": "Highlight the 50% increase in remission likelihood."}, "refers_back_to": null}, {"step_index": 3, "observation": {"text": "Both relapse risk reduction and remission improvement are key metrics.", "image_path": null, "audio_path": null}, "reasoning": "Together, they show the treatment's effectiveness.", "action": {"type": "text_response", "value": "Combine findings for a comprehensive answer."}, "refers_back_to": null}], "task_complexity": "low", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-17", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "For people who are not eligible for a stem cell transplant , immunotherapy with a combination of histamine dihydrochloride ( Ceplene ) and interleukin 2 ( Proleukin ) after the completion of consolidation has been shown to reduce the absolute relapse risk by 14 % , translating to a 50 % increase in the likelihood of maintained remission .", "_validation_note": "The reasoning for each step is logical, the response is correct and sensible, and the information is coherent."}